We rank companies based on fund manager, research analyst and news sentiment
ALLK stock icon

Allakos
ALLK

$1.07
0.94%
 

About: Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.

Employees: 131

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 7 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

1,051% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $96.6K

25% more capital invested

Capital invested by funds: $164M [Q3] → $206M (+$41.7M) [Q4]

2.94% more ownership

Funds ownership: 83.32% [Q3] → 86.26% (+2.94%) [Q4]

9% less funds holding

Funds holding: 116 [Q3] → 106 (-10) [Q4]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

47% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 43

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$1
7%
downside
Avg. target
$4.71
341%
upside
High target
$10
835%
upside

7 analyst ratings

positive
57%
neutral
14%
negative
29%
JMP Securities
Jonathan Wolleben
180%upside
$3
Market Outperform
Maintained
17 Jan 2024
Barclays
Carter Gould
7%downside
$1
Underweight
Maintained
17 Jan 2024
Jefferies
Kevin Strang
40%upside
$1.5
Hold
Downgraded
17 Jan 2024
Jefferies
Kevin Strang
461%upside
$6
Buy
Assumed
8 Dec 2023
JMP Securities
Jonathan Wolleben
835%upside
$10
Market Outperform
Reiterated
28 Nov 2023

Financial journalist opinion